Drug Approval | December 04, 2025
FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
Angelini Ventures has already invested €125 million in 22 startups
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Now a test that offers new precision in prostate cancer detection
Subscribe To Our Newsletter & Stay Updated
